Total Funding
9
27
Total FundingSeed raised
Growth Score
-11 pts
Heat Score
-7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
722538
Primrose Therapeutics is engaged in the development of treatments for polycystic kidney disease.
About the Company
Primrose Therapeutics, Inc. is a biotechnology company focused on the development of treatments for Polycystic Kidney Disease (PKD). PKD is one of the most common life-threatening genetic disorders, affecting 600,000 Americans and 12.5 million people worldwide -- more than cystic fibrosis, muscular dystrophy, hemophilia, Down syndrome and sickle
cell anemia combined. PKD results in the abnormal growth of cells in the kidney, which eventually lead to the development of bilateral kidney cysts and structural destruction of the kidney. The average lifespan of PKD patients is 64 years -- at least a decade shorter than average. No FDA approved therapies currently exist for this devastating disease.
